Flexion Therapeutics Inc (FLXN)

19.55
NASDAQ : Health Care
Prev Close 19.49
Day Low/High 19.02 / 20.25
52 Wk Low/High 7.56 / 23.57
Avg Volume 357.40K
Exchange NASDAQ
Shares Outstanding 27.53M
Market Cap 536.51M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Flexion Therapeutics Announces Presentation Of Phase 3 Data Demonstrating That Extended-Release Zilretta™ Achieves Clinically Significant Improvement Of Pain, Stiffness And Function In Patients With Osteoarthritis Of The Knee

Flexion Therapeutics Announces Presentation Of Phase 3 Data Demonstrating That Extended-Release Zilretta™ Achieves Clinically Significant Improvement Of Pain, Stiffness And Function In Patients With Osteoarthritis Of The Knee

Podium Presentation at the AAHKS Annual Meeting Shows Zilretta Delivers Extended Relief Compared to Immediate-Release Steroid and Placebo

Insiders Seeing Green With FLXN At New 52-Week High

Insiders Seeing Green With FLXN At New 52-Week High

In trading on Thursday, shares of Flexion Therapeutics, Inc. touched a new 52-week high of $22.00/share.

Flexion Therapeutics Announces Appointment Of John Magee as Vice President Of Sales

Flexion Therapeutics Announces Appointment Of John Magee as Vice President Of Sales

- Magee is a seasoned pharmaceutical executive with significant experience building effective sales teams and launching products -

Seeing Some Good Action in Individual Stocks

Seeing Some Good Action in Individual Stocks

An update on the market and my stock of the week, TPI Composites.

Flexion (FLXN) Stock Plunged Today After Announcing Stock Offering

Flexion (FLXN) Stock Plunged Today After Announcing Stock Offering

Flexion (FLXN) stock closed sharply lower on Wednesday after announcing plans to raise $77 million from a stock offering.

Market Digging Metal and Mining Stocks

There is some good speculative trading and metals are the place to be.

Commit To Buy Flexion Therapeutics At $10, Earn 22.8% Annualized Using Options

Commit To Buy Flexion Therapeutics At $10, Earn 22.8% Annualized Using Options

Investors eyeing a purchase of Flexion Therapeutics, Inc. stock, but tentative about paying the going market price of $15.38/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Flexion Therapeutics Enrolls First Patient In Phase 2 Trial Of Zilretta™ Among Type 2 Diabetes Patients With Knee Osteoarthritis

Flexion Therapeutics Enrolls First Patient In Phase 2 Trial Of Zilretta™ Among Type 2 Diabetes Patients With Knee Osteoarthritis

Study to Determine If Zilretta Can Avoid the Hyperglycemia that is Commonly Observed in Diabetic Patients Who Receive Immediate-Release Triamcinolone Acetonide (TCA) Injections for Knee Osteoarthritis

Flexion To Present Pivotal Phase 2b And Phase 3 Results For Zilretta™ At Osteoarthritis Research Society International (OARSI) 2016 World Congress

Flexion To Present Pivotal Phase 2b And Phase 3 Results For Zilretta™ At Osteoarthritis Research Society International (OARSI) 2016 World Congress

Podium presentation highlights results from pivotal clinical trials completed in patients with osteoarthritis (OA) of the knee